Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.
Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.
复制标题
从SARS-COV-2的血清监视中学习，以告知大流行的准备和反应。
DOI：
10.1016/s0140-6736(23)00964-9
复制
发表时间：
2023-07-29
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
2019冠状病毒病疫情凸显了血清监测作为了解人群免疫力、追踪病毒传播和指导公共卫生决策的循证工具的重要性。1自2019冠状病毒病大流行开始以来，在超过145个国家进行了超过4200项血清阳性率研究，检测了超过3400万人的血液样本，2 2023年初，德国国家公共卫生研究所罗伯特·科赫研究所召开了一个关于国际血清学研究的在线研讨会，参与者包括研究机构、国家公共卫生机构、研究所、来自低收入和中等收入国家的区域公共卫生机构参加了会议，并邀请与会者反思经验教训，并就挑战、机遇和今后的步骤得出切实可行的结论（与会团体名单见附录）。自COVID-19疫情爆发以来，与会者在国家或地区层面开展了血清阳性率研究，并共同探讨了如何利用这项投资来最大限度地提高持续的公共卫生效益，并为未来的疫情准备和应对提供信息。在这里，我们讨论与会者确定的主要经验教训。
The COVID-19 pandemic underlined the importance of serosurveillance as an evidence-based tool to understand population immunity, track viral transmission, and guide public health decision making. 1 Since the start of the COVID-19 pandemic more than 4200 seroprevalence studies were done in over 145 countries by testing blood specimens from more than 34 million people, 2 In early 2023, the Robert Koch Institute, Germany’s national public health institute, convened a online symposium about international serological studies that involved research organisations, national public health agencies, institutes, and regional public health agencies from low-income and middleincome countries and invited participants to reflect on lessons learned and draw practical conclusions on challenges, opportunities, and next steps (the participating groups are listed in the appendix). Attendees had implemented seroprevalence studies at the national or regional level since the start of the COVID-19 pandemic, and collectively addressed the questions on how to use this investment to maximise continued public health benefits and to inform future pandemic preparedness and response. Here, we discuss the primary lessons identified by the meeting attendees.